Vor Biopharma Inc. (VOR)
1.37
0.03 (2.24%)
At close: Jan 15, 2025, 9:44 AM
undefined% (undefined)
| Bid | 1.34 |
| Market Cap | 93.94M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | -0.83 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.35 |
| Volume | 66,398 |
| Avg. Volume (20D) | 774,380 |
| Open | 1.36 |
| Previous Close | 1.34 |
| Day's Range | 1.32 - 1.41 |
| 52-Week Range | 0.63 - 2.56 |
| Beta | undefined |
About VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, an...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 168
Stock Exchange NASDAQ
Ticker Symbol VOR
Website https://www.vorbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for VOR stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 777.26% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 weeks ago ·
Source
+51.55%
Vor Bio shares are trading higher after the compan...
Unlock content with
Pro Subscription
1 month ago ·
Source
+26.89%
Vor Biopharma shares are trading higher after the company announced it will present data on its AML therapy at the ASH 2024 annual meeting.
